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Objective: To evaluate multiplex allele speciﬁc polymerase chain reaction as a rapid molec-
ular  tool for detecting multidrug-resistant tuberculosis.
Methods: Based on drug susceptibility testing, 103 isolates were multidrug-resistant tuber-
culosis and 45 isolates were sensitive to isonicotinylhydrazine and rifampin. Primers were
designed  to target ﬁve mutations hotspots that confer resistance to the ﬁrst-line drugs isoni-
azid  and rifampin, and multiplex allele speciﬁc polymerase chain reaction was performed.
Whole-genome  sequencing conﬁrmed drug resistance mutations identiﬁed by multiplex
allele  speciﬁc polymerase chain reaction.
Results: DNA sequencing revealed that 68.9% of multidrug-resistant strains have point muta-
tions at codon 315 of the katG gene, 19.8% within the mabA-inhA promoter, and 98.0% at
three  hotspots within rpoB. Multiplex allele speciﬁc polymerase chain reaction detected
each  of these ﬁve mutations, yielding 82.3% sensitivity and 100% speciﬁcity for isoniazid
resistance,  and 97.9% sensitivity and 100% speciﬁcity for rifampin resistance as compared
to  drug susceptibility testing.Conclusions: The results show that multiplex allele speciﬁc polymerase chain reaction is an
inexpensive and practical method for rapid detection of multidrug-resistant tuberculosis in
developing countries.
and  of greater toxicity.
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uberculosis infection is a global problem due to the high-
isk  of human transmission, morbidity and mortality. Nearly
wo  million deaths and more  than 9 million new cases are
© 20eported  each year, making Mycobacterium tuberculosis the pri-
ary cause of death from a single pathogen.1 The spreading
f  HIV/AIDS and the emergence of the multidrug-resistant
∗ Corresponding author at: Department of Tuberculosis, The First Afﬁlia
eihui 453100, Henan Province, China.
E-mail address: xiawangcn@yeah.net (X. Wang).
413-8670 ©  2013 Elsevier Editora Ltda. 
ttp://dx.doi.org/10.1016/j.bjid.2013.04.008
Este é um artigo Open Access sob a licençastrains of TB (MDR-TB) led to a worldwide resurgence of
tuberculosis2 which poses a serious threat to the global pre-
vention  and control of this disease. The treatment of MDR-TB
requires  the use of second-line drugs. However, these drugs
may  be of minimal therapeutic value, can be more  expensive
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A single gene mutation can induce TB drug resistance.4–6
Studies about the frequency of various gene mutations lead-
ing  to MDR-TB in our region have not been conducted yet.
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Because these speciﬁc mutations are related to changes in
TB  susceptibility to certain drugs, the study of the MDR-TB
mutation spectrum in our local area is helpful to guide the
treatment  of tuberculosis and can inform the development of a
rapid molecular diagnostic test to detect variants of MDR-TB.7
The prevalent point mutations conferring drug resistance to
this pathogen are: mutations in the KatG gene that allow iso-
niazid  or isonicotinylhydrazine (INH) tolerance; mutations of
the  mabA-inhA operon promoter, rpoB or rifampin (RIF) tol-
erance  determining region (RRDR) regions, which induce RIF
tolerance.8
As treatment of MDR-TB is difﬁcult and its transmission
is rapid, the need for developing a rapid diagnostic test to
detect  MDR-TB and effectively prevent the spread of MDR-
TB  in the community is paramount to avoid an epidemic.
The  gold standard for diagnosing MDR-TB is culture-based
drug susceptibility testing (DST). However, the long repli-
cation  time of M.  tuberculosis delays the time to reach a
diagnosis  via DST, and performing DST requires appropriate
laboratory equipment and skilled personnel, making it dif-
ﬁcult  to adapt DST as a routine lab test. Drug resistance is
determined  clinically by observation of non-responsiveness
to standard ﬁrst-line drug therapy and through information
of  history of exposure to MDR-TB. Multiple allele speciﬁc
PCR  (MAS-PCR) allows simultaneous detection of the most
common  INH and RIF tolerance related gene mutations,
which reduces the cost and the dependence upon technical
skills.9
In the present study, we identiﬁed the most common
INH and RIF mutations from previously collected clinical iso-
lates  of MDR-TB using MAS-PCR. Our results show that this
method  is capable of detecting those mutations quickly and
economically, making this method suitable for application in
developing countries.
Materials  and  methods
Isolation  of  M.  tuberculosis
A total of 191 M.  tuberculosis clinical isolates were collected
from  2005 to 2012 at our hospital. DST analysis conﬁrmed that
103  of these isolates were  MDR-TB and 45 isolates were sen-
sitive  to INH and RIF. MAS-PCR was  performed using these
TB  clinical isolates. This study was  conducted in accordance
with  the declaration of Helsinki and approved by the Ethics
Committee of the First Afﬁliated Hospital of Xinxiang Medical
University.  Written informed consent was  obtained from all
participants.
Identiﬁcation  and  drug  sensitivity  tests
Sputum samples were  decontaminated according to the
revised  Petroff method10 and cultured on Lowenstein–Jensen
agar. AccuProbe hybridization test (Gen-Probe) was used
to  conﬁrm that the clones represent M. tuberculosis com-
plex.  Biochemical tests, including nitrate reduction, niacin
test  and 68 ◦C catalase inhibition were  conducted to fur-
ther  classify these isolates.10 DST was  performed using the
Canetti  multiple proportional dilution method. Minimum 1 3;1  7(6):667–671
inhibitory drug concentrations used were 0.2 mg/mL  INH,
40  mg/mL  RIF, 4 mg/mL  streptomycin and 2 mg/mL  ethamb-
utol.
Extraction  of  genomic  DNA
Mycobacterial genomic DNA was  extracted from cultured iso-
lates using the genomic DNA extraction kit (TaKaRa, Dalian,
China).  The quantity and purity of DNA were  determined using
the  spectrophotometric ratio of 260 nm/280 nm.
DNA  sequencing
Double-stranded DNA fragments were  generated using ultra-
sound  and converted to blunt ends with T4 DNA polymerase.
Klenow Exo was  subsequently used to extend the blunt ends.
DNA  was size-selected in a 2% agarose gel. DNA  of 250–250
base  pairs was  cut and recovered using the gel extraction kit
(TaKaRa,  Dalian, China) and a DNA library was  generated using
PCR.
Multiple  allele  speciﬁc  PCR  (MAS-PCR)
MAS-PCR was  designed to detect the ﬁve most common INH
and  RIF resistance-conferring mutations, KatG codon 315,
mab-inhA:  −15, and rpoB codons 516, 526 and 531.11–13 Five
pairs  primers, two allele-speciﬁc primers and three pairs of
general  detection primers were used simultaneously in a
single  PCR to produce a PCR band spectrum detecting all
mutation  variants. The reaction mixture contained the fol-
lowing  primers: rpoB516 (1 pmol), rpoB526 (5 pmol), rpoB531
(32.5  pmol), RIRm (30 pmol), katgOF (1 pmol), katg5R (1 pmol),
inhAP-15  (6 pmol) and inhAPF (6 pmol). The other reagents
used  were  10× PCR buffer (2.5 mL), 50 mM MgCl2 (2 mL), 10 mM
dNTPs  mixture (0.5 mL), 5 U/mL Taq Polymerase (0.1 mL), and
DNA  template (20 ng). The ﬁnal reaction volume was  increased
to  25 L by adding dH2O. PCR parameters were  96 ◦C for 3 min,
95 ◦C for 50 s, 68 ◦C for 40 s, 72 ◦C for 60 s, repeated for 25
cycles, followed by a 72 ◦C extension for 7 min. The PCR prod-
uct  was  puriﬁed by agarose gel electrophoresis and bands were
observed  under UV light.
In  order to improve sensitivity, the two allele-speciﬁc
primers were designed such that the point mutation was
placed  in the second base position from the 3′ end. If the
targeted  position is the wild-type, the allele speciﬁc frag-
ment  would be ampliﬁed to produce a visible band. In
contrast, if the position being targeted contains mutation,
it  will block the ampliﬁcation of that speciﬁc fragment.
An INH and RIF-sensitive isolate will produce ﬁve bands
(Fig.  1). A mutation in any of the ﬁve sites will result in an
ampliﬁcation pattern lacking one or more  of these expected
bands.
Evaluation  of  the  MAS-PCR
The DST, DNA sequencing and MAS-PCR results were  com-
pared  to decide how efﬁciently each technique can detect
INH  and RIF tolerance and to compare their sensitivity and
speciﬁcity.  The reproducibility of the MAS-PCR was  also
assessed.
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Fig. 1 – Band patterns indicating drug resistance proﬁle of
isolates.  Lane 1, H37Rv reference strain (wild-type at all 5
loci);  lane 2, mabA-inhA 215CRT and RpoB D516F double
mutant;  lane 3, KatG S315T and RpoB H526Y double
mutant; lane 4, KatG S315G and RpoB 531L double mutant;
lane  5, mabA-inhA 215CRT, KatG S315T and RpoB H526D
triple  mutant; lane 6, mabA-inhA 215CRT, KatG S315T and
RpoB  S531L triple mutant; and lane 7, DNA ladder.
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f the 191 isolates, 45 were sensitive to INH and RIF, and 103
ere  resistant to both INH and RIF (Fig. 1). Multidrug resistance
etection  by DST was  as follows: 38/103 resistant to INH and
IF,  36/103 resistant to streptomycin, 27/103 resistant to INH,
IF,  streptomycin and ethambutol.
NA  sequencing
n 71/103 (68.9%) isolates, a point mutation was  detected in
atG  codon 315. Of these isolates, 69 isolates harbored the
315T  mutation (67 AGCRACC and 2 AGCRACA). In 20/101
19.8%)  isolates, mutation 215CRT on mabA-inhA operon was
etected.  Of these 20 isolated, four isolates had two point
utations in the operon. RIF resistance mutation is located
t  the drug resistant determined region (DRDR): S531L muta-
ion  was  detected in 80/101 (79.2%), H526D/Y mutation was
etected  in 80/101 (14.9%), and D516F/V mutation was found
n  6/101 (5.9%) isolates. No other mutation was found. In
hort,  mutations in these three sites account for 99/101 (98.0%)
f  RIF resistant isolates. Compared with the gold standard
or  detecting drug resistance, the sensitivity and speciﬁcity
f  DNA sequencing for detecting INH resistance were 82.9%
nd  100%, respectively. The sensitivity and speciﬁcity of DNA
equencing  were 98.0% and 100% for detecting RIF resis-
ance.  Because 17 INH resistant isolates lacked the above
entioned mutations in the two sites, DNA sequencing was
tilized  to detect other potential drug resistance mutation
ites.  A large deletion was  found that extends to the katG
ene,  removing the last 320 bp (e.g., 14.4% of the C-terminus
f  the protein). Three isolates were  found to bear nonsense
utations in codon 198 and 722, which results in a truncated
atG  protein lacking the portion of amino acid 740. More-
ver,  we  found a large 500 bp repeat (Rv3177–Rv3573) in one
solate.3;1 7(6):667–671  669
MAS-PCR  assay
DNA sequencing, DST and MAS-PCR were evaluated for their
respective  abilities to detect the ﬁve target mutation sites.
Compared to DNA sequencing, the sensitivity and speciﬁcity
of  MAS-PCR in detecting common mutations were  both 100%.
In  comparison to DST, the sensitivity and speciﬁcity of MAS-
PCR  in detecting common INH resistant mutations were  82.3%
and  100%, respectively. The sensitivity and speciﬁcity of MAS-
PCR  in detecting common RIF resistant mutations were  97.9%
and  100%, respectively (Table 1). Our results indicate that MAS-
PCR  has a high degree of reproducibility.
Discussion
Single gene mutations in TB can lead to drug resistance. We
designed  a MAS-PCR method for the detection of ﬁve site
mutations, which are related to drug resistance. This method
is  a fast, and relatively inexpensive test and does not need
highly  skilled personnel, making it suitable for application in
remote areas of China. Use of this technique can reduce the
delay  in diagnosis and treatment of MDR-TB.
We found that 68.9% of INH resistant isolates contain a
KatG  S315 T/G mutation and 19.8% contain a 215CRT mutation
in  the mabA-inhA operon. These two mutations accounted for
82.9% of INH resistant MDR isolates. Our results are consis-
tent  with the ﬁndings of others, which showed the mutation
frequency to be 60.4–93.6% in KatG and 18–50% in 215CRT
mabA-inhA.6,14–16 In our region, rpoB codon 531 is the most
common mutation site (79.1%). In contrast, mutation frequen-
cies  at this locus range from 40.1 to 82.4% in MDR-TB isolates
from  Brazil, South Africa, China, North Korea, Vietnam, India
and  Russia.6,14–16 RpoB mutations in codon 516 (5.9%) and
526  (14.9%) accounted for most of the remaining RIF resis-
tant  isolates in our study, which is consistent with the reports
of  mutation frequencies ranging from 2.9 to 16.7% and 5.9
to  40%, respectively. Single RIF resistance is rare and 90% of
RIF-resistant  M.  tuberculosis are also INH resistant strains,17 as
was  also conﬁrmed in the recently developed Xpert MTB/RIF
experiments18 and by our results in this study.
MAS-PCR shows good operability and is 100% accurate
as  compared with DNA sequencing results in detecting INH
and  RIF resistance. Moreover, results from the double blind
operation  using MAS-PCR method in different laboratories
are  highly consistent. Interestingly, MAS-PCR can detect the
H526D  mutation portion of RpoB, but not all resistant strains.
If  MAS-PCR does not detect this particular mutation, this
technique  can still correctly detect 98.0% of rpoB mutation-
containing strains, and 97.1% of RIF-resistant isolates. It is
possible  that these isolates contain heterologous ﬂora com-
posed  with both wild-type and mutation on codon 526 in rpoB
gene,  resulting in the ampliﬁcation of the wild-type PCR prod-
uct.  The whole-genome sequencing data also reveals some
heterogeneity of these isolates.
DNA sequencing did not reveal any common mutation in
16.4%  of INH-resistant and in 1.5% of RIF-resistant isolates.
However, a few isolates contain other gene mutations that
can  allow INH resistance. Three isolates contained mutations
that  are predicted to produce a truncated KatG protein lacking
670  b r a z j i n f e c t d i s . 2 0 1 3;1  7(6):667–671
Table 1 – Comparisons of sensitivity and speciﬁcity between DST and MAS-PCR in detecting INH and RIF resistance (95
cases).
MAS-PCR results DST results Sensitivity (%) Speciﬁcity (%)
No. resistant No. susceptible
INH resistance
Detected 53 0 82.3 100
Not detected 11  31
RIF resistance
rDetected 63 0 
Not detected 1 31
the C-terminus. The C-terminus of KatG protein has enzy-
matic  function,19,20 and the truncated mutation lacking the
C-terminal 41 amino acids is inactivate.20 Although INH resis-
tance  is conferred by KatG truncation,21 the minimum protein
truncation  required to cause INH resistance has not yet been
determined.  We  speculate that the deletion of the C-terminal
19  amino acids is enough to impair the interaction between
subunits and leads to INH resistance.
We also found a D94G mutation inside the KatG protein
in  two isolates. This mutation was  found to be unrelated
to  INH resistance except in one report.22 In this report, the
authors  found a 34GRA mutation inside the ahpC promoter.
In  our study, two isolates contained the KatG D94G and AhpC
P44R  mutations even though AhpC is not obviously associated
with  the INH-resistance because the overexpression of ahpC
in  wild-type M.  tuberculosis does not increase INH resistance.
However, the mutation in ahpC promoter region can be used
as  a useful marker for detecting INH resistance.8 Whether
KatG D94G mutation leads to KatG inactivation or whether
AhpC  P44R mutation can compensate the inactivation of cata-
lase  and peroxidase activity are questions that require further
investigation.
In  addition, in one isolate we found a 500 bp genome
repeat crossing Rv3177–Rv3573c. This area contains nat gene
(Rv3566c),  and this mutated gene confers INH resistance.23
The repeat may  result in the upregulation of nat and increase
the  total activity of the enzyme N-acetyltransferase leading
to  reduced INH efﬁcacy. However, this needs to be proved
experimentally. In ﬁve isolates, we  did not ﬁnd any signiﬁ-
cant  mutation in INH resistance related loci. In one of them,
no  apparent mutation in katG, inhA were  found (except in
rpoB,  where we  found a synonymous mutation), suggesting
that  there may  be another DR mechanism.
It should be pointed out that the design of our study was
retrospective thus not allowing the estimation of the real inci-
dence  of resistance mutations of MDR-TB in the population.
Due  to the use of previously collected specimens, MAS-PCR
were  only assessed based on cultured isolates and has yet to
be  directly assessed using patient’s sputum specimens. It is
necessary to further assess the effectiveness of MDR-TB using
clinical  isolates and conduct prospective studies to assess the
operability  of MAS-PCR relative to DST.Conclusion
Genetic INH and RIF resistance related mutation frequency
in  the MDR-TB isolates in our area is similar to that in other97.9 100
areas. Due to the high sensitivity and speciﬁcity of MAS-PCR
in  detecting MDR-TB, and the characteristics of this technique
including speed, cost-effectiveness and ease of operation,
MAS-PCR might be a good method for routine screening of
MDR-TB.  Further analysis of the genomes of preserved MDR-
TB  isolates will reveal new mutations associated with INH and
RIF  resistance.
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